ClinicalTrials.gg
RecruitingNCT06435000POLARISUpdated Sep 19, 2025

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

An observational study in Stargardt, Stargardt's Disease and Stargardt Disease, sponsored by Splice Bio. Recruiting at 20 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Splice Bio · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
8th of 16
75 · median 63
Started
2024
with 5 others
Observational
16 of 42
8 open now
Primary completion
2026-12
later than 3 of 24 live
Registered
30th of 42
by date

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 8th largest by planned enrollment of the 16 observational ones that give a count, is one of 6 that started in 2024, is one of 16 observational ones, reaches primary completion later than 3 of the 24 other live ones, and was the 30th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

This is an Observational Study to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

This is a multicenter study which will enroll approximately 75 subjects

Read the detailed description

Comprehensive knowledge of a disease is essential to the design and conduct of well-controlled, interventional clinical trials. Understanding of the disease state is important for identifying the patient population for a clinical trial, study duration, and selection of clinically meaningful endpoints.

Observational studies play an important role in the understanding of rare diseases and facilitating effective development of potential therapies. To support clinical research, observational studies can help define the clinical features of a rare disease, rate of progression, pathophysiology, and other important factors. Further, following the course of a disease over time allows investigators to identify demographic variables, genotypic and phenotypic features, and other characteristics that may correlate with disease and outcomes in the absence of treatment. Thus, observational studies are useful in guiding the design of therapeutic studies, including selection of the patient population, trial duration, and the types of outcome measures to evaluate efficacy and safety.

Results of a natural history study evaluating the progression of atrophy secondary to Stargardt Disease have been published using retrospective and prospective cohorts of patients (ProgStar, Strauss et al., 2016).

In summary, the current study is a prospective observational study of patients with STGD1, the aim of which is to further enhance understanding of disease progression and structural and functional markers that can be used to evaluate the efficacy and safety of therapeutic interventions, especially in light of advancements in imaging technology.

03

Conditions studied

  • Stargardt
  • Stargardt's Disease
  • Stargardt Disease
  • STGD1

Browse trials for

Keywords

  • POLARIS
  • Splicebio
  • STGD1
  • ABCA4
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants will be selected that have a genetic and clinical diagnosis of STGD1 and fulfil all other entry criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provide written consent
  2. Are male or female aged 12-65 years old
  3. Have a diagnosis of STGD1 caused by bi-allelic likely pathogenic or pathogenic variants in the ABCA4 gene confirmed genotypically by an accredited genotyping laboratory
  4. Have a history of STGD1 progression within the last 2 years, in the opinion of the investigator.
  5. Eligible eye(s) must have:

    1. BCVA of between 24-88 ETDRS letters, inclusive (20/20 - 20/320 Snellen equivalent, 0.0-1.2 logMAR) at the Screening Visit.
    2. Clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease.
    3. Fundus autofluorescence (FAF) measurement of definitely decreased autofluorescence (DDAF) as measured by the Central Reading Center (CRC).
    4. Total lesion must be imaged in its entirety.
    5. All total lesion borders must be ≥300 microns from all image edges.
  6. Eligible eye(s) must have clear ocular media and adequate pupillary dilation, including no allergy to dilating eyedrops, to permit good quality retinal imaging.

Exclusion criteria

Exclusion Criteria:

  1. Are an immediate family member (e.g., child, sibling) of the Sponsor or study site personnel.
  2. Have any concurrent ocular disease that would affect study procedures or outcomes (e.g., cataracts; subjects can be enrolled 90 days after successful cataract surgery) in eligible eyes.
  3. Have two likely pathogenic or pathogenic variants (not STGD1) in autosomal recessive inherited retinal dystrophy (IRD) genes or a single likely pathogenic or pathogenic variant in autosomal dominant or X-linked IRD genes.
  4. Have had any intraocular surgery or thermal laser within 90 days of study entry or any prior thermal laser in the macular region within the eligible eye(s).
  5. Have any major surgical procedure within 30 days of the Screening Visit or planned or anticipated major surgery during the study period.
  6. Are unwilling to stop taking the following products at Screening and throughout the study:

    1. Supplements containing vitamin A or beta-carotene, liver-based products.
    2. Prescription oral retinoids.
  7. Have actively participated in an therapy study or have received any investigational therapy within 90 days of the Screening Visit or 5 half-lives, whichever is longer. Note: any ophthalmic history of gene therapy, stem cell therapy, surgical implantation of prosthetic retinal chips, or intravitreal or sub-retinal injections exclude the subject from study participation.
  8. Have known serious allergies to the fluorescein dye that might be used to measure intraocular pressure (IOP), ocular dilating drops, topical ocular anesthetic, or any history of anaphylaxis reaction.
  9. Have a history of amblyopia in the eligible eye(s).
  10. Have any significant ocular or non-ocular disease/disorder (or medication and/or laboratory test abnormalities) which, in the opinion of the investigator and with concurrence of the Medical Monitor, may either put the subject at risk because of participation in the study, may influence the results of the study, or affect the subject's ability to participate in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Document disease progression based on change from baseline in lesion size as measured by DDAF on FAF imaging

    Time frame: 96 weeks

Secondary outcomes

  1. Change from baseline in ellipsoid zone (EZ) area as measured by SD-OCT

    Time frame: 96 weeks

  2. Change from baseline in BCVA using ETDRS

    Time frame: 96 weeks

  3. Change from baseline in LLVA using ETDRS

    Time frame: 96 weeks

  4. Change from baseline in retinal sensitivity based on macular microperimetry

    Time frame: 96 weeks

  5. Change from baseline in contrast sensitivity scores

    Time frame: 96 weeks

  6. Change from baseline using Patient Reported Outcome Questionnaires

    Time frame: 96 weeks

07

Study locations

20 of 20 sites recruiting
  • Shiley Eye Institute
    San Diego, California 92093, United States
    Recruiting
    • Site 108 · Principal investigator
  • UCHealth Sue Anschutz-Rodgers Eye Center
    Aurora, Colorado 80045, United States
    Recruiting
    • Site 109 · Principal investigator
  • Vitreo Retinal Associates
    Gainesville, Florida 32607, United States
    Recruiting
    • Site 114 · Principal investigator
  • Bascom Palmer Eye Institute
    Miami, Florida 33136, United States
    Recruiting
    • Site 104 · Principal investigator
  • Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Site 107 · Principal investigator
  • Wilmer Eye Institute, Johns Hopkins University MD 21287
    Baltimore, Maryland 21287, United States
    Recruiting
    • Site 111 · Principal investigator
  • Massachusetts Eye and Ear Infirmary
    Boston, Massachusetts 02114, United States
    Recruiting
    • Center for Clinical Research · Contact
    • Site 105 · Principal investigator
  • Kellogg Clinical Research Center
    Ann Arbor, Michigan 48105, United States
    Recruiting
    • Site 106 · Principal investigator
  • Columbia University Medical Center
    New York, New York 10032, United States
    Recruiting
    • Site 113 · Principal investigator
  • CUIMC/Edward S. Harkness Eye Institute
    New York, New York 10032, United States
    Recruiting
    • Site 112 · Principal investigator
  • Duke Eye Center
    Durham, North Carolina 27710, United States
    Recruiting
    • Site 110 · Principal investigator
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
    • Site 103 · Principal investigator
  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Recruiting
    • Site 102 · Principal investigator
  • University of Wisconsin, Madison
    Madison, Wisconsin 53715, United States
    Recruiting
    • Site 101 · Principal investigator
  • Universitätsklinikum Bonn, Klinik für Augenheilkunde
    Bonn, 53127, Germany
    Recruiting
    • Site 302 · Principal investigator
  • University Eye Hospital Tübingen
    Tübingen, 72076, Germany
    Recruiting
    • Site 301 · Principal investigator
  • Moorfields Eye Hospital
    London, London EC1V 2PD, United Kingdom
    Recruiting
    • Site 201 · Principal investigator
  • Leeds Teaching Hospitals NHS Trust
    Leeds, LS9 7T, United Kingdom
    Recruiting
    • Site 204 · Principal investigator
  • University of Manchester - The Old St Mary's Hospital
    Manchester, M13 9WL, United Kingdom
    Recruiting
    • Site 203 · Principal investigator
  • Oxford Eye Hospital
    Oxford, OX3 9DU, United Kingdom
    Recruiting
    • OUH under the Eye Research Group Oxford · Contact
08

References and documents

Related links

Individual participant data

Plan to share: No — Sponsor will wait until data fully analyzed and published before considering sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2024 (actual). Primary completion is estimated for Dec 2026, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
Mar 29, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Feb 2027
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06435000
Lead sponsor
Splice Bio
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Mar 29, 2024
Primary completion
Dec 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 19, 2025

Study contacts

SpliceBio
Contact
clinicaltrials@splice.bio
+34 934 02 04 56

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion